Zai Lab Limited Earnings Recaps
Q3 2025
Nov 7, 2025
Zai Lab's Q3 2025 results reflect strong advancements in its clinical pipeline, particularly the promising early data for Zoci, while the company's commercial operations in China demonstrate steady growth despite a complex environment.
Key takeaways
- Zoci (ZL-1310) shows a 68% overall response rate and 94% disease control rate in heavily pretreated extensive stage small cell lung cancer patients, suggesting strong efficacy potential.
- The company is on track for its first global approval by 2027 or early 2028, with ongoing enrollment in registrational Phase III trials.
- Zai Lab reports continued profitability within its commercial business in China, although growth is at a slower pace than anticipated amid a dynamic market.
- Significant advancements in the pipeline include the entry of IL-13/IL-31 bispecific antibody into Phase I and continued progress with innovative assets and late-stage programs.
- The company emphasizes a commitment to delivering impactful therapies and long-term value for shareholders while navigating regulatory and competitive challenges.